A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2014-02-12
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to compare the safety, tolerability, and anti
tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with
metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new
preparation of the active drug paclitaxel. It contains the same medication as the
prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment
of metastatic breast cancer after failure of combination chemotherapy for metastatic disease
or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is approved by the FDA for
the treatment of melanoma. In this study, ABI-007 and Dacarbazine will be tested as therapy
for people who have not yet had any cancer treatment for the diagnosis of metastatic
melanoma.